Male study dosing
1–12 mgShared trial protocol; not sex-specific
MGMT RESEARCHPRODUCT CONCEPT
RESEARCH COMPOUND
RETROD Retatrutide 10 mg
A 10 mg lyophilized research compound for investigating GLP-1, GIP, and glucagon signaling, appetite regulation, and metabolic pathways.
$100.00 CADPer vial · 10 mg option
Shipping & Returns
Prices are in Canadian dollars and include tax. Shipping is calculated in your checkout order summary.
Delivery usually takes 3–7 days after dispatch, depending on your location. Allow up to 10 days for remote areas. Canada Post or FedEx is selected based on your mailing address.
Usual dispatch time
In-stock items usually ship the same day when payment is received before 12:00 p.m. EST. Some larger and wholesale orders ship the following day.
Check the product page for current availability, sourcing or preorder information before ordering. Dispatch timing is separate from the carrier’s delivery time.
No returns or refunds.
We do not accept returns or offer refunds, except where required by applicable law. Once our research compounds leave the warehouse, they cannot be returned to stock for resale.
This policy does not limit any rights or remedies required by applicable law.
Every compound vial includes one FREE 3 mL BAC Water and one compound / BAC pair holder. Any strength. No minimum purchase. Bundles count their included water toward this offer. Extra BAC Water is $10.00 CAD each.
Prices in CAD before tax. E-transfer accepted · Credit cards coming soon.
Includes FREE 3 mL BAC Water + a compound / BAC pair holder with every vial.
FORMATLyophilized powder
VIAL AMOUNT10 mg
INTENDED USELaboratory research
Retatrutide beyond weight loss →
Retatrutide long-term research →
Female study dosing
1–12 mgShared trial protocol; not sex-specific
Frequency in trials
Once weeklySelected cited trial only
Route in trials
SubcutaneousInvestigational study material
Reported half-life
Approximately 6 daysPublished molecule/formulation; not this vial
Post-cycle PCT
Not establishedNo validated PCT protocol is provided
Study-reference information only. Any amounts, schedules, routes, or pharmacokinetic values describe the cited study material, not directions for using MGMT Research vials. Male and female labels do not imply separate recommendations. Target or maintenance study arms are not starting-dose instructions.
RESEARCH DESCRIPTION
RETROD · Published research
Published clinical studies & evidence limits
A randomized phase 2 trial investigated the underlying molecule in adults with obesity or overweight and a weight-related condition. At 48 weeks, mean body-weight reductions ranged from 8.7% to 24.2% across study groups, compared with 2.1% with placebo. Gastrointestinal adverse events were common and dose-related. These findings concern trial-manufactured material and supervised protocols; they do not establish the effects or suitability of MGMT Research vials.
Molecular structure
RETROD is a synthetic 39-residue peptide containing noncanonical amino acids and a C20 fatty diacid side chain. It interacts with GIP, GLP-1, and glucagon receptors.
Historical development
Discovery research published in 2022 investigated combining three receptor activities within one engineered peptide.
Laboratory research applications
Laboratory applications include receptor binding, cyclic AMP signaling, structural analysis, and chromatographic assessment of peptide identity and degradation.
Published findings describe the material and protocols used by the investigators. MGMT Research does not claim equivalent results for its products and does not recommend their use in humans or animals.
For laboratory research use only. Not for human or animal consumption, treatment, diagnosis, or prevention of disease.
Product specifications & handling +
- Product
- RETROD · Retatrutide
- Selected quantity
- 10 mg
- Form
- Lyophilized powder
- Receptors
- GLP-1R · GIPR · GCGR
- Testing
- COA pending · SideChain Analytics
- Origin / dispatch
- Canadian supplier partner / Toronto
Supplier-provided storage guidance
This guidance applies to MGMT’s supplied peptide vials. Follow the actual product label and any batch-specific instructions.
Before reconstitution · lyophilized powder
Our supplier advises refrigeration at 2–8 °C for shorter-term storage and freezer storage when the powder will not be reconstituted soon. Confirm the freezer temperature in the product-specific storage instructions.
The supplier-stated estimates for lyophilized material are 12–18 months refrigerated and up to 24 months frozen. These are not independently verified stability results. Never exceed the expiry date on the label; receiving or freezing a vial does not restart its shelf life.
After reconstitution · prepared solution
For MGMT’s supplied formulations, our supplier advises keeping the prepared solution at 2–8 °C, protected from light, without freezing. This is product-specific guidance, not a rule for every peptide solution.
MGMT sets a maximum of three months after reconstitution. Follow any shorter limit specified by the product label, supplier, or validated laboratory procedure. This cap does not establish stability or microbiological suitability for three months.
If no preparation-specific storage period has been established, do not assume the solution can be kept for three months. The powder’s expiry does not establish a use-by date for the prepared solution.
In-stock items usually ship the same day when payment is received before 12:00 p.m. EST. Some larger and wholesale orders ship the following day.
COA pending. Purity and net-content results will be published when the batch-specific report is available.
MIX EASYYour mixture.
Your mixture.
Made clear.
Select your compound, vial amount, diluent volume, and sample amount. Our calculator converts your inputs into a concentration, volume, and U-100 syringe marking.
01
Set your mixture
mg
mL
Enter an example amount to calculate its volume.
02
Your measurement
RETROD
20units
0.2 mL of solution per sample
U-100 scale1 mL = 100 units
Concentration10 mg/mL
Full samples per vial5
THE CALCULATION
2 mg ÷ 10 mg/mL = 0.2 mL
How to read this calculator +
Concentration = vial amount ÷ solution volume. Sample volume = sample amount ÷ concentration. U-100 scale units = volume in mL × 100; these are volume markings, not units of compound potency.
This example assumes the final solution volume equals the diluent volume entered, and that the compound dissolves completely. It does not establish solubility, compatibility, stability, or an administration dose.
Decimal measurements are mathematical results and may fall between markings. Full samples are rounded down; they do not account for handling losses.
The calculator checks concentration mathematics. It does not select a treatment dose or establish compatibility, sterility, or stability. BAC Water is the diluent, not a peptide.
SIDE EFFECTS & CONSIDERATIONS
What the research reports.
In the Phase 2 study, gastrointestinal adverse events were most common and increased with dose. Heart-rate increases were also observed. Longer-term safety remains under investigation.
Retatrutide remains investigational, with no regulatory approval. Research-grade MGMT Research vials are not clinical-trial medication.
Product-specific considerations
- Independent identity, purity, and content results are pending for RETROD.
- A labeled 10 mg quantity does not establish a therapeutic dose.
- Mixing calculations cannot establish sterility, stability, or suitability for administration.
DOSAGE GUIDELINES / STUDY CONTEXT
Vial amount is not a dose.
Your selected RETROD vial is labeled 10 mg. There is no approved male or female dosing regimen for this research product.
Published Phase 2 study arms
Adults were assigned 1, 4, 8, or 12 mg once weekly for 48 weeks under a controlled protocol. These are study details, not self-use instructions.
Dosing Studied in Clinical Trials
TRIUMPH-4 · 12 mg target-dose arm
Lilly reported once-weekly dosing with four-week escalation steps. Expressed as treatment weeks, the planned sequence was:
- Weeks 1–4: 2 mg once weekly
- Weeks 5–8: 4 mg once weekly
- Weeks 9–12: 6 mg once weekly
- Weeks 13–16: 9 mg once weekly
- Week 17 onward: 12 mg once weekly, the assigned target dose
The trial also included a 9 mg target-dose arm. Participants followed a controlled study protocol with clinical oversight; this is research information, not a suggested RETROD self-use or maintenance plan.
Source: Lilly’s TRIUMPH-4 study summary ↗Want the full walkthrough?
Explore the research context, vial quantities and concentration calculations in our beginner’s guide.
Retatrutide research basics →Laboratory sample amounts and preparation procedures should come from your validated protocol. Enter those amounts into Mix Easy to check the volume calculation.
Open Mix Easy ↗Read the original trial ↗